By performing blood tests on cancer patients, it is possible to monitor the recurrence of cancer in patients with advanced melanoma skin cancer during treatment.
Research staff from the Manchester Cancer Institute in the United Kingdom conducted a study of circulating tumor DNA in blood samples from seven patients with advanced melanoma. Their findings demonstrate that cancer recurrence can be judged by tracking the level of CtDNA in the blood.
In addition, the researchers also found that if mutations such as NRAS and PI3K are detected, it is highly likely that cancer will recur in the course of cancer treatment.
Most melanoma patients have a certain therapeutic effect during the initial medical treatment. But often after a year, these tumors will appear resistant to cancer treatment. Therefore, this method of detecting CtDNA in patients can help doctors find and carry out individualized treatment for patients, and help patients get the best results in cancer treatment.
BRAF gene mutations are present in 40-50% of melanoma patients. These skin cancer patients can use the targeted drug vemurafenib or dabrafenib to treat cancer. However, these two classes of drugs are not suitable for cancer patients carrying the normal BRAF gene, or tumor resistance may occur during a short period of treatment.
If this happens, these patients can use some immunotherapeutics, such as some monoclonal antibodies: Pembrolizumab, Nivolumab, and Ipilimumab. If the patient's genetic mutation has been detected in the early stage of treatment, personal information such as medical treatment can be improved, and individualized treatment can improve the prognosis of the patient, and the survival rate and quality of life of the patient can be improved.
Richard MaraisB, a skin cancer specialist from the Cancer Research Center, said: "If we can find signs of recurrence of skin cancer as early as possible, we can quickly develop an optimal individualized treatment plan. It is worth investigating and developing new ones. Detection technology. Through our detection technology, we hope to find the recurrence of cancer at the earliest time, start a new treatment plan as soon as possible. Get more time for patients to accompany their loved ones. Although our current work has found a specific Direction, but before entering clinical trials, more preclinical experiments are needed to validate the technology."
Sleep Improving Extract,Sleep Aid Extract,Peaceful Sleep Extract,Ziziphi Seed Extract
Shaanxi Zhongyi Kangjian Biotechnology Co.,Ltd , https://www.zhongyiherbs.com